Jump to content

Search the Community

Showing results for tags 'metformin'.

More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


  • Forums
    • CR Science & Theory
    • CR Practice
    • Chitchat
    • General Health and Longevity
    • CR Recipes
    • Members-Only Area
  • Community


  • Paul McGlothin's Blog
  • News
  • Calorie Restriction News Update


  • Supporting Members Only
  • Recipes
  • Research

Product Groups

  • CR IX
  • CRSI Membership
  • Conference DVDs

Find results in...

Find results that contain...

Date Created

  • Start


Last Updated

  • Start


Filter by number of...


  • Start



Website URL

Found 6 results

  1. This retrospective study was done on a very large number of metformin treated diabetics with pair matched non-diabetics. Diabetics had higher BMI, but were also more often on treatment for high lipid and hypertension. Unadjusted all cause mortality of diabetics was equal to controls (an achievement by itself), where as adjusted mortality was lower! Link to full text paper: http://onlinelibrary.wiley.com/doi/10.1111/dom.12354/full
  2. All, At the recent CR conference, Dr Richard Miller from the University of Michigan gave a great talk on the Interventions Testing Program, a NIA-sponsored, rigorous, multi-center effort to investigate the potential of various drugs, supplements and nutriceuticals to extend lifespan in mice. Dr. Miller shared with us some results which have now been published. Here is a good summary of the latest results. It looks like the most promising interventions were metformin+rapamycin, acarbose, and 17-α-estradiol (in males only). I'm not planning on running out to take any of these, but I find acarbose interesting. It works by blocking the breakdown of carbohydrates, and suppressing hunger - in many ways like eating extra dietary fiber (a controversial topic itself) as discussed here on the Dietary Fiber - Health Promoter or Anti-CR Hunger-Suppressor? thread. --Dean
  3. All: You may or may not be aware, but a couple of years ago Dr. Nir Barzilai proposed a trial to test metformin as an "anti-aging" drug in normal aging people (see press below). Late last year, FDA gave the go-ahead, with the provisional indication of "multimorbidity". Now the Global Healthspan Policy Institute, a lobbying group representing the Alliance for Aging Research and its partners, including SENS Research Foundation: http://www.agingresearch.org/Home http://healthspancampaign.org/ ... is asking for scientific organizations and individuals to sign on to a campaign to push Congress to fund the TAME study, in THIS YEAR's appropriation cycle. I last night got an email from the American Aging Association (AGE) indicating that they need organizational endorsements and individual petition-signers to get on board by TUESDAY, MARCH 1. Public stuff from GHPI: https://healthspanpolicy.org/metformin-campaign/ http://tame.healthspanpolicy.org/ Some in-depth press: http://www.pharmaceutical-journal.com/news-and-analysis/features/why-the-use-of-anti-ageing-drugs-could-delay-the-development-of-chronic-diseases/20200663.article http://www.sciencemag.org/news/2015/09/feature-man-who-wants-beat-back-aging http://www.wsj.com/articles/scientists-new-goal-growing-old-without-disease-1426542180 Now, it seems clear to me that metformin is a pretty unpromising candidate, except in the slightly cynical sense that mild overweight and insulin resistance is so common in the 70+ crowd that they may get some good-looking results that have little to do with even messing-with-metabolism on aging per se. But the sheer fact of having a trial funded and going that targets aging would potentially move the needle on public perception, and unless it goes disastrously wrong should help cement FDA's one-time decision to authorize such a trial into a precedent, eliminating the problem that "aging" is not currently a "disease" against which pharma can develop drugs. So, speaking as an individual and not in my role in the CR Society Board pending any eleventh-hour decision on an official organizational endorsement, I would like to strongly urge everyone to sign the petition — or (better yet, since form-letter electronic petitions generally get ignored) reach out directly to your congressional reps via their official websites: http://www.house.gov/representatives/find/ http://www.senate.gov/general/contact_information/senators_cfm.cfm ... via both their own, on-site email form and their Congressional office telephone, urging them to support and use the petition letter (click on the link in the petition that says "this personalized letter") only as model language, revising it individually to express your support on the key point: "I urge you to I urge you to support the funding of landmark medical research in the "Peer Reviewed Medical Research Program" in the Department of Defense's budget, particularly in support of the new TAME/Metformin study, to open the door to a new class of medications that protect and restore the healthy function and productivity of the human healthspan – our years of health." Again, they need this all in their arsenal by THIS TUESDAY.
  4. Sthira


    Just checking in and wondering if anyone here has -- um -- reconsidered pilling metformin? Why? Sighs of impatience: time is passing, beautiful people, and not much progress appears imminent on this scientism-y age-slowing gig. So anyone gambling with low doses? 250 or 500?
  5. All, Here is an MIT Technology Review article on a new study just getting underway to study the potential anti-aging effects of the CR mimetic rapamycin in dogs. It is directed by CR-friendly aging researcher Matt Kaeberlein from the University of Washington. Here are a couple highlights from the very informative article: Over time cells are degraded by several factors, including damaged DNA, misfolded proteins, and excessive inflammation. This degeneration can’t be stopped altogether, but researchers have found a surprising number of ways to slow it down in yeast cells and other living things. The common thread seems to be calorie restriction. If you cut down the food supply enough, a series of biochemical changes switch the body into a kind of lower gear so it can hunker down for survival. Rapamycin and other drugs that appear to slow aging in animals work by triggering this same biochemical pathway. The idea, says Harvard Medical School researcher David Sinclair, is to trick the body into acting as if it’s running out of energy and putting more effort into long-term survival. <snip> [A]t high doses, rapamycin can raise blood sugar and thereby increase the risk of diabetes. It causes mouth lesions known as canker sores. Researchers originally worried that because it works as part of an immune-suppressive cocktail for organ transplants, it would raise the risk of infection. But then a study last year in Science Translational Medicine showed that a derivative of the drug seemed to enhance human immunity following a flu shot. <snip> Rapamycin, originally isolated from soil bacteria on Easter Island and named after the island’s native name, Rapa Nui, is one of five drugs that have extended the lives of mice in studies. But it probably will be a lot easier to achieve life extension in mice than in people. Still, he and a number of others in the field are optimistic about rapamycin because it extended mouse life spans between 9 percent and 14 percent, and it worked whether mice began getting the drug during middle age or very late in their short lives. Moreover, it prevented cardiovascular damage and memory loss. That suggests that it might lengthen the period in which people are healthy and functional rather than drawing out a period of decline. <snip> The study includes only larger dogs, since they age faster than small dogs for reasons that are not completely understood, says University of Washington biologist Matt Kaeberlein, who is heading the study. The researchers plan to eventually follow 32 dogs in an initial phase, after which they’ll examine the data. One quarter of the dogs will get a placebo, not because dogs are subject to the placebo effect but to prevent bias in the owners who will be reporting regularly on their dogs’ health. So far the owners have reported no notable side effects, Kaeberlein says. “The last thing we want to do,” he says, “is harm people’s pets.” The article says the dogs in the study are all at least 6 years old. Since the larger breeds they are using typically live 8-14 years, these dogs are late middle age / early elderly, and it will be several years before longevity results are available. The whole article is worth reading. --Dean